Skip to main content
Premium Trial:

Request an Annual Quote

Aiming for CLIA Certification, DermTech Begins Validation of Melanoma Test


DermTech said this week that it has begun commercial validation testing of its proprietary pigmented lesion assay, a non-invasive qPCR-based test for melanoma.

The San Diego-based company recently completed the build-out of a commercial laboratory space in nearby La Jolla, Calif. The company needs to complete analytical and clinical validation studies of its assay in order to receive regulatory certification under CLIA requirements.

DermTech recently raised $5.6 million in a Series B financing led by Jacobs Investment Company, and will use a portion of these funds to complete the validation of its assays.

The company's assays analyze the expression level of multiple gene targets using Life Technologies' OpenArray quantitative real-time PCR system (PCR Insider 8/22/2013). DermTech's initial assay will identify expression consistent with melanoma. The test uses an adhesive-patch method to collect cells from pigmented lesions including melanomas, allowing for non-invasive sample collection.

DermTech is conducting the validation studies in collaboration with Northwestern University and the University of Pittsburgh Medical Center.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.